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A role for dendritic cells (DCs) in autoimmunity remains to be fully delineated. In this issue of Immunity,
Teichmann et al. (2010) reveal critical functions for DCs in augmenting, but surprisingly not in initiating,
spontaneous autoimmune disease.Dendritic cells (DCs) are key players in the
induction and maintenance of adaptive
immunity, acting as sentinels and con-
veying antigenic information to T cells. In
addition to driving effector T cell res-
ponses against pathogens, DCs also
regulate T cell responses against self-
antigens and innocuous foreign antigens
by inducing the differentiation of regula-
tory T (Treg) cells, T cell anergy, or clonal
deletion of effector T cells specific for
such antigens. Autoimmunity occurs
when these decision mechanisms go
awry and effector T cell responses are
elicited toward self-antigens. Delineating
the pathways that regulate the activation
of autoreactive T cells is critical to our
understanding of the breakdown in self-
tolerance and development of autoimmu-
nity. Interestingly, although the role of T
and B lymphocytes in autoimmunity is
well described, and indeed biologics
targeting these cell lineages are used in
the treatment of autoimmune diseases
such as rheumatoid arthritis and systemic
lupus erythematosus (SLE), far less is
known of DC involvement in autoimmune
disease. It is widely assumed that
because of the fundamental role of DCs
in initiating T cell responses to infectious
agents, DCs play an essential pathologic
role in autoimmune disease by presenting
self-antigens to autoreactive T cells.
In this issue of Immunity, Teichmann
et al. (2010) address this question by
adopting a DC ablation model in combi-
nation with the widely used MRL.Faslpr
mouse model of lupus. CD11c-DTA
mice, in which CD11c-expressing cells
express the diphtheria toxin a (DTA)
chain, were generated previously and
demonstrated an impairment of antiviral
and antiparasite immunity in the virtual840 Immunity 33, December 22, 2010 ª2010absence of conventional DCs (cDCs)
(Birnberg et al., 2008; Ohnmacht et al.,
2009). By generating such mice on
the MRL.Faslpr lupus-prone background,
Teichmann et al. (2010) studied the devel-
opment and progression of lupus in
a constitutively cDC-deficient scenario.
This elegant model allows the investiga-
tion of cDC functions during the natural
onset and progression of autoimmune
disease. The work concludes that cDCs
are crucial in regulating the magnitude of
spontaneously arising autoimmune
disease, with CD11c-DTA mice exhibiting
less severe disease.
One of the most interesting observa-
tions in this study is that although cDCs
were critical for the expansion of preacti-
vated T cells, they were not necessary
for the initial activation of T and B cells.
The authors arrived at this conclusion
because in CD11c-DTA lupus-prone
mice, spontaneous T cell activation oc-
curred and in fact the proportion of
T cells maintaining a naive phenotype
was small. This is surprising and is in stark
contrast to the well-documented function
of cDCs as the primary cell type capable
of priming naive T cell responses during
infection, by use of this and other ablation
systems (Birnberg et al., 2008; Jung et al.,
2002; Ohnmacht et al., 2009). Neverthe-
less, Teichmann et al. (2010) do demon-
strate that activated T cells are reduced
in cDC-deficient animals, albeit modestly
(Figure 1). In addition, T helper 1 cell dif-
ferentiation and IFN-g production were
attenuated in cDC-deficient animals.
This finding is not entirely unprecedented
as it was demonstrated previously that
lymph node CD4+ T cell responses
to a model antigen remained intact inde-
pendently of cDCs in CD11c-DTA miceElsevier Inc.(Birnberg et al., 2008). Furthermore, spon-
taneous autoimmunity developed in
CD11c-DTA mice generated by one
group (Ohnmacht et al., 2009), but not
another (Birnberg et al., 2008), and this
was associated with an increased fre-
quency of activated (CD44hiCD62Llo)
CD4+ T cells. For further elucidation of
the contribution of autoreactive T cells to
the activated T cell pool in CD11c-DTA
mice, it would also be interesting to
compare naive and activated T cell subset
ratios in the CD11c-DTA colony that does
not develop autoimmunity. The discrep-
ancies between studies in CD11c-DTA
mouse strains suggest a role of cDCs in
autoimmunity that depends on environ-
mental conditions and/or genetic back-
ground (Birnberg et al., 2008; Ohnmacht
et al., 2009). There are also differences
in DC deletion between different CD11c-
DTA strains. In the CD11c-DTA colony
that develops autoimmunity and in the
CD11c-DTA lupus-prone mice, plasma-
cytoid DCs and Langerhans cells are
ablated, whereas these remained present
in the colony generated by Jung and
colleagues (Birnberg et al., 2008; Ohn-
macht et al., 2009).
Because CD11c+ cells are efficiently
and constitutively deleted in the present
study by Teichmann et al. (2010), the
data suggest that antigen-presenting
cells that lack high amounts of CD11c
expression can initiate T cell responses
in an autoimmune setting. In direct con-
trast to this conclusion, however, another
study recently demonstrated a key role
for cDCs in the breach of self-tolerance
in another autoimmune model by using
the conditional CD11c-diptheria toxin
receptor (DTR) DC ablation approach
(Benson et al., 2010). Because these two
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Figure 1. A Model for the Role of Dendritic Cells in Autoimmunity
When DCs are replete (left), DCs present self-antigen to autoreactive T cells, which proliferate, differen-
tiate, and acquire effector functions such as IFN-g production. Activated CD4+ T cells also undergo
cognate interactions with antigen-specific B cells, forming germinal centers (not shown) and antibody-
secreting, long-lived plasma cells. In addition, a major source of autoantibodies in lupus, short-lived
plasmablasts, are derived from extrafollicular responses that might involve direct DC-B cell interactions.
In contrast, when DCs are absent (right), other as yet undefined APCs initiate the activation of autoreactive
CD4+ T cells that are in turn able to drive the humoral response. However, full expansion of T and B
cells fails in DC-deficient animals. Finally, plasmablast numbers are reduced or absent, possibly because
of the absence of direct DC-B cell interactions or cytokine support provided by plasmacytoid DCs, thus
lowering autoantibody titers. The net effect of reduced T and B cell activation, autoantibodies, and inflam-
matory cytokines in the absence of DCs is reduced development of experimental systemic lupus erythe-
matosus (SLE).
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of autoimmunity and different DC ablation
systems that are known to affect myeloid
populations differently (e.g., one is con-
stitutive whereas the other transiently
depletes DCs) (Bar-On and Jung, 2010),
it is unclear whether the nature of the
ablation model or the autoimmune di-
sease itself accounts for the disparate
outcomes. Undoubtedly, establishing a
comprehensive understanding of the role
of DCs in initiating autoimmune res-
ponses will require further work in multiple
models of DC ablation and autoimmune
disease. Caveats do exist with the
CD11c-DTA system; for example, the It-
gax gene shows activity in non-DCs,
including some T cells, NK cells, plasma-
blasts, and macrophages (Bar-On and
Jung, 2010). In addition, very small
numbers of residual CD11chi DCs remain
in these mice, although the authorsmake a compelling case that residual
DCs would not likely be sufficient to
account for retention of T cell activation
in CD11c-DTA MRL.Faslpr mice. Further-
more, in contrast to the conditional
CD11c-DTR system, constitutive ablation
of DCs from early development may allow
formation of compensatory pathways.
Importantly, these and other authors
have excluded a potential role of impaired
negative selection in the thymus (Birnberg
et al., 2008); however, central tolerance is
impaired in theCD11c-DTAmouse colony
that develops spontaneous autoimmunity
(Ohnmacht et al., 2009).
It will be interesting in the future, when
less toxic systems than CD11c-DTR
mice become available, to use a condi-
tional DC ablation system to allow the
role of DCs at distinct stages of disease
progression in lupus to be dissected.
Another interesting question is the role ofImmunity 33, Dlymphoid versus nonlymphoid organ
DCs in augmenting autoreactive res-
ponses. Teichmann et al. (2010) show that
although DC ablation in the kidneys was
effective, lymphocytic infiltrates were still
present and suggest that nonlymphoid
DCs may drive in situ expansion of these
infiltrates. In addition, an exciting next
step would be to identify the cells respon-
sible for priming autoreactive T and B
cells in the cDC-deficient situation.
Previous studies by the same group
have demonstrated that the antigen-pre-
senting functions of B cells are critical
for T cell activation in MRL.Faslpr mice.
Consistent with this, the proportion of
T cells that maintain a naive phenotype
is much greater in B cell-deficient Fas-
intact MRL/+ mice. However, it also
remains possible that macrophages and/
or other monocyte-derived cells may
perform this function in the absence of
CD11chi cDCs.
Although the initiation of autoimmunity
did not depend on DCs, Teichmann
et al. (2010) observed a marked depletion
of plasmablasts and autoantibodies in
CD11c-DTAMRL.Faslpr mice. DCs clearly
impact antibody responses in an indirect
fashion via their role in T cell priming.
However, work here and by other investi-
gators suggest that direct DC-B inter-
actions, taking place outside the B cell
follicle, may also be important (Qi et al.,
2006). DCs possess nondegradative
pathways for antigen that enables presen-
tation of native antigen to the B cell
receptor (Bergtold et al., 2005). Teich-
mann et al. (2010) show that while T cell
activation occurs, short-lived plasma-
blasts, which originate in extrafollicular
areas of the lymph node, are reduced in
DC-depleted mice (Figure 1). Plasma-
blasts represent a major source of auto-
antibodies in MRL.Faslpr mice, and
further, class switching of autoantibodies
is reduced in the absence of cDCs.
Consistent with this, autoantibody titers
are reduced in the absence of cDCs, but
serum Ig titers are unchanged. One
caveat is that plasmablasts express
CD11c and can be deleted in CD11c-
DTR mice upon diptheria toxin treatment
(Bar-On and Jung, 2010). Thus, it remains
possible that the loss of plasmablasts in
CD11c-DTA MRL.Faslpr mice is not the
result of deficiency in DCs but rather a
direct depletion of plasmablasts. How-
ever, the idea that DCs may regulate theecember 22, 2010 ª2010 Elsevier Inc. 841
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tent with previous studies on human cells
by Pascual and Banchereau in which
plasmacytoid DCs participated critically
in the generation of plasmablasts in vitro
by providing type I interferon and other
cytokine support (Jego et al., 2003).
Teichmann et al. (2010) rightfully point
out that a key future direction will be to
delineate the distinct role that plasmacy-
toid DCs play in this model of autoimmu-
nity compared with the role of other DC
subsets.
Finally, the authors also show that
numbers of Treg cells are reduced in the
absence of cDCs because of both re-
duced expansion and survival. In con-
trast, in both colonies of CD11c-DTA
mice, Treg cell numbers were reported
to be normal (Birnberg et al., 2008; Ohn-
macht et al., 2009). However, it has been
demonstrated previously that inducible
depletion of DCs results in a reduction in
Treg cells and an increased risk of devel-
oping autoimmunity (Darrasse-Jeze et al.,
2009). Thus, the role of DCs in maintaining
Treg cell numbers remains controversial,842 Immunity 33, December 22, 2010 ª2010with discrepancies probably reflecting
differences in the ablation strategies
being used. Even in studies wherein Treg
numbers were not reduced, it remains
possible that alterations in the Treg cell
repertoire in terms of antigen specificity
and/or subset composition existed.
Although it is clear from the recently
growing literature on the role of DCs in
autoimmunity that we still have much to
learn and resolve in the area, the exciting
findings provided here by Teichmann
et al. provide affirmative support for
important and practical concepts: DCs
appear to be genuine therapeutic targets
in autoimmune disorders, and inhibition
of their function or numbers during
ongoing, established disease may prove
to be beneficial.REFERENCES
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